Login | Register

MabThera Confirmed As Beneficial For Treating Non-Hodgkin’s Lymphoma

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded, after conducting a quality review of the genetically engineered monoclonal antibody MabThera, that the batches of rituximab, the active substance of MabThera, that were produced in the U.S. at the Vacaville manufacturing site do not present a risk to public health...

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *